Almac Discovery, a member of the Almac Group, has announced a research collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) focusing on the generation of novel small molecule inhibitors against specified Deubiquitinase (DUB) targets for the treatment of a range of neurodegenerative and other diseases.